BioCentury | Apr 23, 2012
Strategy

A couple of bucks more

After turning down a $2.6 billion offer from long-time partner GlaxoSmithKline plc , Human Genome Sciences Inc. has three options: try to get more from GSK, look for a white knight, or essentially reinvent itself yet...
BioCentury | Apr 2, 2012
Finance

Doubling down

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news. At least one...
BC Week In Review | Mar 19, 2012
Company News

Anthera autoimmune news

Anthera said it will restructure and reduce headcount by about 45% to save cash after discontinuing development of cardiovascular product varespladib. Anthera, which had 38 employees at Dec. 31, 2011, said the move will allow...
BioCentury | Mar 19, 2012
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/16 cls Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Cowen Steve Scala Downgrade Neutral (from outperform) -51% $3.17 Deutsche Bank Navdeep Singh Price target Buy Piper Jaffray...
BC Extra | Mar 13, 2012
Financial News

Anthera plummets after discontinuing development of varespladib

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) fell $2.86 (45%) to $3.56 on Monday after announcing late Friday that it will discontinue development of cardiovascular compound varespladib for all indications. The secretory phospholipase A2 ( sPLA2 ) inhibitor showed a...
BC Week In Review | Mar 12, 2012
Clinical News

Varespladib methyl: Development discontinued

Anthera discontinued development of cardiovascular product varespladib due to "lack of efficacy" in the double-blind, placebo-controlled, international Phase III VISTA-16 trial to treat ACS. Anthera made the decision based on a recommendation from the study's...
BC Extra | Mar 10, 2012
Top Story

Varespladib trial shows lack of efficacy

Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) will discontinue development of cardiovascular compound varespladib for all indications after it showed a lack of efficacy in the Phase III VISTA-16 trial to treat acute coronary syndrome (ACS). Anthera President...
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
BC Week In Review | Dec 19, 2011
Clinical News

Varespladib methyl: Phase III ongoing

Anthera said that a DSMB recommended for the fifth time the continuation of the double-blind, placebo-controlled, international Phase III VISTA-16 trial based on a review of safety data from available patients. The study is evaluating...
BC Week In Review | Aug 8, 2011
Clinical News

Varespladib methyl: Phase III ongoing

Anthera disclosed in its 2Q11 earnings that in July a DSMB recommended for the fourth time the continuation of the double-blind, placebo-controlled, international Phase III VISTA-16 trial based on a review of safety data from...
Items per page:
1 - 10 of 49